Moderna and Merck Present Intismeran Therapy at ESMO Congress
4 reports, 3 independent
Updated Sep 24
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Moderna and Merck jointly presented intismeran autogene therapy at the European Society for Medical Oncology Congress in Madrid. Intismeran autogene is an investigational mRNA-based individualized neoantigen therapy. Moderna announced that three abstracts detailing the therapy were accepted for presentation at the ESMO Congress 2026.
Why it matters
The presentation of intismeran, a personalized cancer vaccine developed with Moderna, is viewed as a major clinical milestone for both companies. Bank of America noted that clinical catalysts across Merck's oncology pipeline, including intismeran, could lead to a re-rating of Merck's shares.
Who's involved
- ModernaJointly developed intismeran autogene therapy.
- MerckJointly developed intismeran autogene therapy.
- European Society for Medical OncologyHosted the congress where the therapy was presented.
Keep exploring
The entities involved
-
Moderna
American biotechnology company
-
Merck
public company in Indonesia
-
European Society for Medical Oncology
Professional organisation
Related events
- Evaxion will present clinical trial data at the ESMO Congress 2025 in Berlin, utilizing therapy from Merck Sharp & Dohme.
- Pliant Therapeutics announced its presentation at the European Society for Medical Oncology (ESMO) Congress on October 1, 2026.
- Researchers presented Phase 3 clinical data at the European Society for Medical Oncology (ESMO) Congress on September 21, 2026.
- AbbVie presented clinical data at the European Society for Medical Oncology (ESMO) Congress held in Madrid.